| Stage-based Exercise Promotion Study (NCT01289145) | Freie Universität Berlin | 2011-02-01 |
| The Vitamin B Status in Type 2 Diabetes (VITA) Study (NCT03447275) | Rima Obeid | 2011-01-01 |
| Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes (NCT01276288) | Boehringer Ingelheim | 2011-01-01 |
| Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (NCT01272193) | Novo Nordisk A/S | 2011-01-01 |
| A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus (NCT01273558) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2011-01-01 |
| A Study of LY2409021 in Patients With Type 2 Diabetes (NCT01241448) | Eli Lilly and Company | 2011-01-01 |
| Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects (NCT01272973) | Novo Nordisk A/S | 2011-01-01 |
| TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy (NCT01303315) | MetaCure (USA), Inc. | 2011-01-01 |
| Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756 (NCT01278160) | Novo Nordisk A/S | 2011-01-01 |
| The Effect of Anakinra on Insulin Secretion (NCT01285232) | Radboud University Medical Center | 2011-01-01 |
| MSC and MC in Type 2 Diabetes Mellitus (NCT01719640) | Fuzhou General Hospital | 2011-01-01 |
| A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption (NCT01366287) | Pfizer | 2011-01-01 |
| Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes (NCT01215955) | Eli Lilly and Company | 2010-12-01 |
| A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus (NCT01230749) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2010-12-01 |
| Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives. (NCT01244646) | AstraZeneca | 2010-12-01 |
| OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy (NCT01182493) | Medtronic MiniMed, Inc. | 2010-12-01 |
| Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (NCT01203111) | Sanofi | 2010-12-01 |
| Effect of Meal Frequency on Insulin Resistance in Subjects With Type 2 Diabetes (NCT01277471) | Institute for Clinical and Experimental Medicine | 2010-12-01 |
| Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes (NCT01289119) | Takeda | 2010-12-01 |
| ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination (NCT01204580) | Sanofi | 2010-12-01 |
| Molecular and Clinical Profile of Diabetes Mellitus and Its Complications (NCT01105858) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2010-11-16 |
| CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (NCT01243424) | Boehringer Ingelheim | 2010-11-11 |
| A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India (NCT01212133) | Novo Nordisk A/S | 2010-11-01 |
| A Study of LY2608204 in Patients With Type 2 Diabetes (NCT01247363) | Eli Lilly and Company | 2010-11-01 |
| Synbiotics and Low Grade Inflammation in Obese Subjects (NCT01235026) | University of Chile | 2010-11-01 |
| A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects (NCT01248364) | Boehringer Ingelheim | 2010-11-01 |
| Changing Diabetes® World Tour (NCT01437072) | Novo Nordisk A/S | 2010-11-01 |
| Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus (NCT01236404) | PhaseBio Pharmaceuticals Inc. | 2010-11-01 |
| A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) (NCT01191268) | Eli Lilly and Company | 2010-11-01 |
| A Study Of PF-05175157 In Healthy Volunteers (NCT01274663) | Pfizer | 2010-11-01 |
| A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment (NCT01253304) | Eli Lilly and Company | 2010-11-01 |
| Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes (NCT01232491) | Novo Nordisk A/S | 2010-10-29 |
| GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes (NCT01217112) | Jazz Pharmaceuticals | 2010-10-01 |
| Confronting Unequal Eye Care in Pennsylvania (NCT01179555) | Wills Eye | 2010-10-01 |
| Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus (NCT01226043) | Sanofi | 2010-10-01 |
| Effects of Saxagliptin on Endothelial Function (NCT01319357) | University of Erlangen-Nürnberg Medical School | 2010-10-01 |
| The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male (NCT01840982) | Chonbuk National University Hospital | 2010-10-01 |
| Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability (NCT01211197) | Boehringer Ingelheim | 2010-10-01 |
| Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy (NCT01215097) | Boehringer Ingelheim | 2010-10-01 |
| Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control (NCT01214239) | Boehringer Ingelheim | 2010-10-01 |
| Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen (NCT01165684) | Novo Nordisk A/S | 2010-10-01 |
| Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles (NCT01231984) | Becton, Dickinson and Company | 2010-10-01 |
| A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes (NCT01159938) | Eli Lilly and Company | 2010-10-01 |
| Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics (NCT01357876) | GlaxoSmithKline | 2010-10-01 |
| Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041) (NCT01223339) | Merck Sharp & Dohme LLC | 2010-10-01 |
| Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues (NCT01585506) | Novo Nordisk A/S | 2010-09-20 |
| Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes (NCT01226966) | Novo Nordisk A/S | 2010-09-01 |
| Bridging the Gap by Transitional Care (NCT01330121) | Cook County Health | 2010-09-01 |
| A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus (NCT01215968) | Eli Lilly and Company | 2010-09-01 |
| Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus (NCT01193218) | Boehringer Ingelheim | 2010-09-01 |
| Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study (NCT01194830) | Boehringer Ingelheim | 2010-09-01 |
| Comprehensive Add on Study in Japan (NCT01204294) | Boehringer Ingelheim | 2010-09-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin (NCT01210001) | Boehringer Ingelheim | 2010-09-01 |
| Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes (NCT01724645) | Chonbuk National University Hospital | 2010-09-01 |
| Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (NCT01179048) | Novo Nordisk A/S | 2010-08-31 |
| Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus (NCT01169818) | Sanofi | 2010-08-01 |
| Trial of Different Dosages' Ge Gen Qin Lian Decoction in the Treatment of Type 2 Diabetes (NCT01219803) | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 2010-08-01 |
| Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (NCT01212913) | Sanofi | 2010-08-01 |
| Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients (NCT01147627) | Sun Yat-sen University | 2010-08-01 |
| A Multiple Dose Study Of PF-05161704 In Healthy Volunteers (NCT01202266) | Pfizer | 2010-08-01 |
| Nighttime Dosing of Antihypertensive Drugs in Type 2 Diabetes (NCT01158625) | University of Aarhus | 2010-08-01 |
| Exercise Training and Type 2 Diabetes (NCT01234155) | Rigshospitalet, Denmark | 2010-08-01 |
| A National Study of the Chronic Disease Self-Management Program (NCT01845857) | Stanford University | 2010-08-01 |
| Post Prandial Glucose Control Proof-of-Principle (NCT01326299) | Abbott Nutrition | 2010-08-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes (NCT01167881) | Boehringer Ingelheim | 2010-08-01 |
| 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks (NCT01183013) | Boehringer Ingelheim | 2010-08-01 |
| Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics (NCT01324921) | Abbott Nutrition | 2010-08-01 |
| Safety Study of BMS-823778 in Subjects With Type 2 Diabetes (NCT01111955) | Bristol-Myers Squibb | 2010-07-01 |
| Call-2-Health: Preventing Type II Diabetes (NCT01827826) | Kaiser Permanente | 2010-07-01 |
| Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes (NCT01159600) | Boehringer Ingelheim | 2010-07-01 |
| The Effect of a Nutritional Supplement in Individuals With Type 2 Diabetes Mellitus: a Pilot Study (NCT01505803) | University of Sydney | 2010-07-01 |
| Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. (NCT01122979) | Sanofi | 2010-07-01 |
| A Single Dose Study Of PF-05161704 In Healthy Volunteers (NCT01183715) | Pfizer | 2010-07-01 |
| BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). (NCT01131676) | Boehringer Ingelheim | 2010-07-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes (NCT01177813) | Boehringer Ingelheim | 2010-07-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment (NCT01164501) | Boehringer Ingelheim | 2010-07-01 |
| Optimizing Audit and Feedback for Primary Care (NCT00996645) | Sunnybrook Health Sciences Centre | 2010-07-01 |
| Understanding of Genetic Risk Information for Type 2 Diabetes (NCT01186354) | Duke University | 2010-07-01 |
| A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics (NCT01147861) | GlaxoSmithKline | 2010-07-01 |
| Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (NCT01117350) | Sanofi | 2010-07-01 |
| The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial) (NCT01137812) | Janssen Research & Development, LLC | 2010-07-01 |
| A Drug Interaction Study of Albiglutide and Digoxin (NCT01147718) | GlaxoSmithKline | 2010-06-11 |
| A Drug Interaction Study With Albiglutide and Warfarin (NCT01147731) | GlaxoSmithKline | 2010-06-04 |
| Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy (NCT01163721) | Gilead Sciences | 2010-06-01 |
| A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes (NCT01149421) | Eli Lilly and Company | 2010-06-01 |
| Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™) (NCT01135992) | Novo Nordisk A/S | 2010-06-01 |
| Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers (NCT01146886) | Boehringer Ingelheim | 2010-06-01 |
| The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone) (NCT01106690) | Janssen Research & Development, LLC | 2010-06-01 |
| An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment (NCT01064414) | Janssen Research & Development, LLC | 2010-06-01 |
| A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes (NCT01154881) | Novo Nordisk A/S | 2010-06-01 |
| Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes (NCT01129258) | Pfizer | 2010-06-01 |
| A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus (NCT01106651) | Janssen Research & Development, LLC | 2010-06-01 |
| Exercise Training in Patients With Coronary Heart Disease and Type 2 Diabetes (NCT01232608) | Oslo University Hospital | 2010-06-01 |
| Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study (NCT01130480) | Hoffmann-La Roche | 2010-05-31 |
| A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus (NCT01031108) | Sirtris, a GSK Company | 2010-05-28 |
| A Drug Interaction Study of Simvastatin and Albiglutide (NCT01147692) | GlaxoSmithKline | 2010-05-19 |
| Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042) (NCT01096667) | Merck Sharp & Dohme LLC | 2010-05-17 |
| A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes (NCT01134224) | Novo Nordisk A/S | 2010-05-01 |
| The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea) (NCT01106625) | Janssen Research & Development, LLC | 2010-05-01 |
| The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial) (NCT01106677) | Janssen Research & Development, LLC | 2010-05-01 |